---
title: "CapForce Inc. (CFOR.US)"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/CFOR.US.md"
symbol: "CFOR.US"
name: "CapForce Inc."
industry: "生物技术"
datetime: "2026-03-10T06:36:06.367Z"
locales:
  - [en](https://longbridge.com/en/quote/CFOR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CFOR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CFOR.US.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/CFOR.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/CFOR.US.md)


# CapForce Inc. (CFOR.US)

## 公司概况

CapForce Inc.是一家精准医疗公司，开发和商业化分子微生物学解决方案，针对美国及国际上的危及生命的传染病。该公司的产品包括 Unyvero 应用卡、Unyvero 系统、Acuitas AMR 基因检测产品和 SARS CoV-2 检测套件。它还提供实验室服务；合作服务，包括资助的软件安排；以及许可安排服务。此外，该公司还提供上市赞助和咨询服务

| 项目 | 详情 |
|------|--------|
| 行业 | 生物技术 |
| 交易所 | US Market |
| 官网 | [www.opgen.com](https://www.opgen.com) |

## 关键驱动因素
> *AI 分析的影响该股票表现的关键因素*


## Longbridge Financial Score™: A
> *Longbridge Financial Score™ — Longbridge 独家多因子评级模型*
> 更新时间: 2026-03-09T04:30:14.000Z

**综合: A (0.18)**

**行业**: 生物技术

| 指标 | 数值 |
|--------|-------|
| 行业排名 | 5 / 407 |
| 行业中位数 | D |
| 行业均值 | C |

- **风格**: 成长型 - 公司主要业务处在成长期的股票。
- **规模**: 小盘型 - 公司经营有较高的成长性和波动性，易于获得较高的投资收益。

**综合评分**: A

#### 风格得分 评分: 

| 指标 | 数值 | 评级 |
|-----------|-------|--------|
| 营业收入同比 | 610.97% |  |
| 净利润同比 | 167.66% |  |
| 市净率 | 29.37 |  |
| 股息率 | 0.00% |  |

#### 规模得分 评分: 

| 指标 | 数值 | 评级 |
|-----------|-------|--------|
| 市值 | 298367811.00 |  |
| 营业收入 | 9000000.00 |  |

#### 多维评分 评分: A

| 指标 | 数值 | 评级 |
|-----------|-------|--------|
| 净资产收益率（ROE） | 102.11% | A |
| 净利率 | 76.04% | A |
| 毛利率 | 0.00% | E |
| 营业收入同比 | 610.97% | A |
| 净利润同比 | 167.66% | A |
| 总资产同比 | 131.07% | A |
| 净资产同比 | 240.16% | A |
| 现金流净利率 | 134.12% | C |
| 运营现金流同比 | 610.97% | A |
| 资产周转率 | 0.99 | A |
| 资产负债率 | 19.63% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - CapForce Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "风格得分",
      "grade": "",
      "indicators": [
        {
          "name": "营业收入同比",
          "value": "610.97%",
          "rating": ""
        },
        {
          "name": "净利润同比",
          "value": "167.66%",
          "rating": ""
        },
        {
          "name": "市净率",
          "value": "29.37",
          "rating": ""
        },
        {
          "name": "股息率",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "规模得分",
      "grade": "",
      "indicators": [
        {
          "name": "市值",
          "value": "298367811.00",
          "rating": ""
        },
        {
          "name": "营业收入",
          "value": "9000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "多维评分",
      "grade": "A",
      "indicators": [
        {
          "name": "净资产收益率（ROE）",
          "value": "102.11%",
          "rating": "A"
        },
        {
          "name": "净利率",
          "value": "76.04%",
          "rating": "A"
        },
        {
          "name": "毛利率",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "营业收入同比",
          "value": "610.97%",
          "rating": "A"
        },
        {
          "name": "净利润同比",
          "value": "167.66%",
          "rating": "A"
        },
        {
          "name": "总资产同比",
          "value": "131.07%",
          "rating": "A"
        },
        {
          "name": "净资产同比",
          "value": "240.16%",
          "rating": "A"
        },
        {
          "name": "现金流净利率",
          "value": "134.12%",
          "rating": "C"
        },
        {
          "name": "运营现金流同比",
          "value": "610.97%",
          "rating": "A"
        },
        {
          "name": "资产周转率",
          "value": "0.99",
          "rating": "A"
        },
        {
          "name": "资产负债率",
          "value": "19.63%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## 估值分析

| 指标 | 当前值 | 行业排名 | 最高 | 中位 | 最低 |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 45.37 | 53/407 | - | - | - |
| PB | 29.97 | 426/407 | - | - | - |
| PS (TTM) | 33.83 | 221/407 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## 同业比较

| 排名 | 名称 | 盈利 | 成长 | 运营 | 财务安全 | 现金流 | 评级 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel制药 (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## 参考链接

- [公司概况 — 简介、高管、股东、业务构成](https://longbridge.com/zh-CN/quote/CFOR.US/overview.md)
- [财务报表 — 利润表、资产负债表、现金流、分红方案](https://longbridge.com/zh-CN/quote/CFOR.US/norm.md)
- [相关新闻](https://longbridge.com/zh-CN/quote/CFOR.US/news.md)
- [公告 — 公司公告与监管文件](https://longbridge.com/zh-CN/quote/CFOR.US/filings.md)

---

> **免责声明: 本文仅供参考，不构成任何投资建议。**